Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cyclacel Pharmaceuti (CYCC)

Cyclacel Pharmaceuti (CYCC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,251
  • Shares Outstanding, K 2,239
  • Annual Sales, $ 40 K
  • Annual Income, $ -11,210 K
  • EBIT $ -10 M
  • EBITDA $ -10 M
  • 60-Month Beta 0.15
  • Price/Sales 352.51
  • Price/Cash Flow N/A
  • Price/Book 2.78
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -123.32
  • Most Recent Earnings $-0.98 on 08/13/25
  • Next Earnings Date 11/11/25
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend 0.150 on 04/29/25
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -6.23
  • Growth Rate Est. (year over year) +16,135.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.92 +7.52%
on 09/10/25
9.52 -33.14%
on 08/13/25
-2.69 (-29.67%)
since 08/11/25
3-Month
3.08 +106.65%
on 07/07/25
19.87 -67.96%
on 07/24/25
+1.63 (+34.45%)
since 06/11/25
52-Week
3.08 +106.65%
on 07/07/25
597.60 -98.93%
on 10/22/24
-255.24 (-97.57%)
since 09/11/24

Most Recent Stories

More News
Bio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd.

KUALA LUMPUR, Malaysia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (Nasdaq: BGMS, Nasdaq: BGMSP) (“Bio Green Med” or the “Company”), a company engaged in diversified industries,...

CYCCP : 5.05 (-4.36%)
BGMS : 1.4400 (-4.00%)
BGMSP : 3.40 (-8.85%)
CYCC : 6.37 (-5.98%)
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

KUALA LUMPUR, Malaysia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...

CYCCP : 5.05 (-4.36%)
CYCC : 6.37 (-5.98%)
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

         - Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis - KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals,...

CYCCP : 5.05 (-4.36%)
CYCC : 6.37 (-5.98%)
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER

CYCCP : 5.05 (-4.36%)
CYCC : 6.37 (-5.98%)
CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT

CYCCP : 5.05 (-4.36%)
CYCC : 6.37 (-5.98%)
Cyclacel Pharmaceuticals Announces Stock Split

CYCCP : 5.05 (-4.36%)
CYCC : 6.37 (-5.98%)
Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock

CYCCP : 5.05 (-4.36%)
CYCC : 6.37 (-5.98%)
CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

CYCCP : 5.05 (-4.36%)
CYCC : 6.37 (-5.98%)
CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

CYCCP : 5.05 (-4.36%)
CYCC : 6.37 (-5.98%)
CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT

CYCCP : 5.05 (-4.36%)
CYCC : 6.37 (-5.98%)

Business Summary

CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside...

See More

Key Turning Points

3rd Resistance Point 7.74
2nd Resistance Point 7.36
1st Resistance Point 6.86
Last Price 6.37
1st Support Level 5.98
2nd Support Level 5.60
3rd Support Level 5.10

See More

52-Week High 597.60
Fibonacci 61.8% 370.49
Fibonacci 50% 300.34
Fibonacci 38.2% 230.19
Last Price 6.37
52-Week Low 3.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar